Recommendations for the management of hepatitis C virus infection among people who inject drugs.
about
KASL clinical practice guidelines: management of hepatitis CIdentifying and characterizing hepatitis C virus hotspots in Massachusetts: a spatial epidemiological approach.Access to healthcare insurance and healthcare services among syringe exchange program clients in Massachusetts: qualitative findings from health navigators with the iDU ("I do") Care Collaborative.Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study.Medical and Behavioral Approaches to Engage People Who Inject Drugs Into Care for Hepatitis C Virus Infection.Financial Incentives for Adherence to Hepatitis C Virus Clinical Care and Treatment: A Randomized Trial of Two Strategies.Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C.Cost-Effectiveness of Hepatitis C Treatment for People Who Inject Drugs and the Impact of the Type of Epidemic; Extrapolating from Amsterdam, the NetherlandsHepatitis C Treatment Uptake among Patients Who Have Received Opioid Substitution Treatment: A Population-Based Study.The Impact of Direct-Acting Antivirals in the Hepatitis C-Sustained Viral Response in Human Immunodeficiency Virus-Infected Patients With Ongoing Barriers to Care.Successful treatment of chronic hepatitis C with triple therapy in an opioid agonist treatment program.Comment on "Hepatitis C and the Sex Trade".Direct-acting antiviral agents for HCV infection affecting people who inject drugs.Hepatitis C: Review of the Epidemiology, Clinical Care, and Continued Challenges in the Direct Acting Antiviral Era.Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs.HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs.Healthcare contact and treatment uptake following hepatitis C virus screening and counseling among rural Appalachian people who use drugs.Initiating HCV treatment with direct acting agents in opioid agonist treatment: When to start for people co-infected with HIV?Primary Care and Hepatology Provider-Perceived Barriers to and Facilitators of Hepatitis C Treatment Candidacy and Adherence.High prevalence of willingness to use direct-acting antiviral-based regimens for hepatitis C virus (HCV) infection among HIV/HCV coinfected people who use drugs.Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005-2014: The HITS-p study.Dual sexual and drug-related predictors of hepatitis C incidence among sex workers in a Canadian setting: gaps and opportunities for scale-up of hepatitis C virus prevention, treatment, and care.The cost impact of outreach testing and treatment for hepatitis C in an urban Drug Treatment Unit.High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic.Elimination of HCV as a public health concern among people who inject drugs by 2030 - What will it take to get there?Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials.Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials.Addressing reimbursement disparities for direct-acting antiviral therapies for hepatitis C virus infection is essential to ensure access for all.Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study.Excluding people who use drugs or alcohol from access to hepatitis C treatments – Is this fair, given the available data?New developments and opportunities for preventing hepatitis C virus (HCV) among people who use and inject drugs-announcing an Addiction series.Why is there still hepatitis C transmission in Australian prisons? A case report.Policy responses to hepatitis C in the Nordic countries: Gaps and discrepant reporting in the Hep-Nordic study.Preference option randomized design (PORD) for comparative effectiveness research: Statistical power for testing comparative effect, preference effect, selection effect, intent-to-treat effect, and overall effect.Global Mortality Burden of Cirrhosis and Liver Cancer Attributable to Injection Drug Use, 1990-2016: An Age-Period-Cohort and Spatial Autocorrelation Analysis.Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies.Insights on the Russian HCV Care Cascade: Minimal HCV Treatment for HIV/HCV Co-infected PWID in St. Petersburg.Treatment advocate tactics to expand access to antiviral therapy for HIV and viral hepatitis C in low- to high-income settings: making sure no one is left behind.The impact of methadone maintenance therapy on access to regular physician care regarding hepatitis C among people who inject drugs.Outpatient directly observed therapy for hepatitis C among people who use drugs: a systematic review and meta-analysis.
P2860
Q26752471-9A95C9D3-A572-4645-A173-366FE8C988E8Q33587555-777822A1-E7A0-480F-BCF1-782184B693A2Q33706376-055E8786-5F4C-4DCF-A497-69B4FBDBDD56Q33795847-82096865-6A9A-4110-BA43-72AAF297931FQ33853664-5F4C1F17-BA17-46AD-84B4-F5D0C57D2B7FQ33878388-50BF5E83-A57F-4991-9D9A-954E6B54D5F3Q36079786-4F288720-A688-481D-85B3-F73C4556DF1CQ36155257-B7B8BED7-90BC-42DA-81DB-F81EF8A40473Q36192804-9E38EB17-D3B4-4A3A-BEA1-4B5A6A16E839Q36382060-5FD757BF-26AE-4ECF-8F02-65956C89A549Q36802839-ED7A6C3C-9ADF-4961-8E6A-1AE3B146A893Q36997031-0C029B8A-5859-43AC-BD35-CA7F7C74B1FFQ38613271-8C30E8E4-6D95-4A56-892C-3D45AC04FAB3Q38635796-C33707C5-C094-4A0E-8F46-BFD01A2867C6Q38661825-6F349E43-C5BF-4617-B090-8E7A64D5B113Q38692113-165C084D-36FD-4B34-A05D-454E5CCECE85Q38710078-1504566F-51FA-461C-B6FB-D3BC6F6CE60DQ38746105-84E91C5E-D78F-4D9F-ADB8-91123A76582DQ38775528-EF3139EA-96D2-44CF-999B-41D953D7D415Q38907436-FBDB54BB-6275-47E8-A588-22CD8AD99BE5Q38931620-AE731788-7006-42BE-BDF3-62F66B5B1CDCQ39061664-2D0B162A-C6B4-41CB-8049-91235223FFBDQ39449112-FF0F5EE3-D71B-4230-8B49-89094949FA1DQ40082158-18E8A4CF-8F2D-407D-B2F9-78130B091214Q40092669-BF85AF44-A68F-495E-BD43-F93AB9DDB55FQ40565822-B0F2B4AC-38AF-4CA6-98E7-7FD88FF20F97Q40565832-D9181380-9081-49F4-A6A8-95E43D4B866AQ40641871-D4B78019-C9FD-49CF-96C6-D7A5EB2B2690Q40959924-F90105FD-DFF7-4CF1-92C1-110EDCB71DABQ43895313-2E84D21A-793C-43EC-8675-EC0BBB3B3E95Q45328522-6F264D62-6202-4919-90CA-6913CDD82C09Q47138778-7172CF00-D528-438B-920D-BDDD2E6BF3B9Q47547903-648D5DB0-5760-46B3-AAB5-A57BF1011CCEQ47620289-73E1C145-6743-4376-8FC1-92276F86AFE1Q47800804-C555907B-AB89-45B8-9C46-0E72BDC87D9CQ49953662-A51BDB75-3A1E-4BBF-B0EA-B82A64F2709DQ52312138-E7364501-9F6A-47BA-8487-B53DF2A9971BQ52597000-0F8D4DD8-D971-4F36-86BF-EC97D526475BQ52631124-6F6FD3DB-E1EA-44A5-BBE5-D06B29DCDEB8Q53281101-AA3E68B6-8449-4603-BFE6-D89662E1B07A
P2860
Recommendations for the management of hepatitis C virus infection among people who inject drugs.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Recommendations for the manage ...... among people who inject drugs.
@en
type
label
Recommendations for the manage ...... among people who inject drugs.
@en
prefLabel
Recommendations for the manage ...... among people who inject drugs.
@en
P2093
P2860
P50
P1476
Recommendations for the manage ...... among people who inject drugs.
@en
P2093
Achim Kautz
Alain Litwin
Alessio Aghemo
Geert Robaeys
Gregory J Dore
International Network for Hepatitis in Substance Users
Jordan J Feld
Jude Byrne
Julie Bruneau
Lynn E Taylor
P2860
P304
P356
10.1016/J.DRUGPO.2015.07.005
P407
P577
2015-07-17T00:00:00Z